Fig. 3

Knockdown of EREG activated the p38 MAPK and Erk signalling pathways in DPSCs. a, b Western blot results and quantitative analysis of the expression of phosphorylated p38 MAPK and phosphorylated Erk in EREGsh and Scramsh DPSCs. β-Actin was used as an internal control. c, d Western blot results and quantitative analysis of the expression of phosphorylated Erk in DPSCs after treatment with 20 μmol/L Erk‐specific inhibitor PD98059 for 1 h in DPSCs. β-Actin was used as an internal control. e, f Western blot results and quantitative analysis of the expression of phosphorylated p38 MAPK in DPSCs after treatment with 20 μmol/L p38 MAPK‐specific inhibitor SB203580 for 1 h in DPSCs. β-Actin was used as an internal control. Error bars represent the SD (n = 3). One-way ANOVA with the post hoc Bonferroni test were used to test statistical significance. *P ≤ 0.05. **P ≤ 0.01